
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is a clinical-stage biotechnology company utilizing generative AI and high-throughput biology to develop novel protein therapeutics, notably ABS-201 (PRLR), currently in Phase 1/2a trials for Pattern Hair Loss (PHL). With promising preclinical data and a well-established market need for alternative treatments, Absci's approach may offer a differentiated and potentially more effective solution for a significant portion of the ~8-18% of women suffering from endometriosis. However, as with all early-stage biotech companies, there is no guarantee of success in the clinic.
Bears say
Absci is a biotechnology company that uses artificial intelligence and synthetic biology to develop novel biologic drugs for various diseases. However, the negative outlook is due to the competitive landscape and potential manufacturing risks associated with third-party suppliers. Additionally, there is uncertainty surrounding the company's ability to secure funding and successfully bring its candidates through clinical trials. While Absci has promising candidates, there is still a need for improvement in clinical outcomes and the company may face challenges in differentiating its products from existing treatments. Overall, there are various factors that could hinder Absci's success and negatively impact its stock.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares